Bryostatin-1 in Treating Patients With Recurrent Non-Hodgkin's Lymphoma

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed non-Hodgkin's lymphoma
• Working formulation low-, intermediate-, and high-grade histologies eligible
• Mantle cell and marginal zone lymphoma eligible
• Relapse after at least 1 doxorubicin-containing regimen required
• No more than 2 prior chemotherapy regimens
• One prior biologic therapy in addition to the 2 prior chemotherapy regimens allowed
• No prior bone marrow transplantation
• Ineligible for treatment on higher priority protocols
• Patients eligible for bone marrow transplantation may be treated to reduce tumor bulk
• Bidimensionally measurable disease required
• No history of primary or metastatic CNS disease
• PATIENT CHARACTERISTICS:
• Age: Any age
• Performance status: Zubrod 0-2
• Life expectancy: Greater than 12 weeks
• Absolute neutrophil count at least 1,000/mm3
• Platelet count at least 100,000/mm3
• Bilirubin no greater than 1.8 mg/dL
• Transaminases no greater than 2.5 times normal
• Creatinine no greater than 1.5 mg/dL OR creatinine clearance greater than 70 mL/min
• No HIV antibody
• No serious intercurrent illness
• No pregnant or nursing women
• Effective contraception required of fertile patients throughout study and for 1 year thereafter
• PRIOR CONCURRENT THERAPY:
• At least 4 weeks since prior therapy (6 weeks since mitomycin) and recovered